Last reviewed · How we verify

Methotrexate plus ENBREL or ENBREL alone — Competitive Intelligence Brief

Methotrexate plus ENBREL or ENBREL alone (Methotrexate plus ENBREL or ENBREL alone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed Small molecule Live · refreshed every 30 min

Target snapshot

Methotrexate plus ENBREL or ENBREL alone (Methotrexate plus ENBREL or ENBREL alone) — Wyeth is now a wholly owned subsidiary of Pfizer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Methotrexate plus ENBREL or ENBREL alone TARGET Methotrexate plus ENBREL or ENBREL alone Wyeth is now a wholly owned subsidiary of Pfizer marketed

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methotrexate plus ENBREL or ENBREL alone — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-plus-enbrel-or-enbrel-alone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: